Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04592822
Other study ID # WD-1602-1001
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date January 6, 2021
Est. completion date December 6, 2021

Study information

Verified date October 2020
Source Hong Kong WD Pharmaceutical Co., Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be a single-center, randomized, single-dose, open-label, two-treatment, two-period, two-sequence crossover bioequivalence study to compare the rate and extent of absorption of WD-1602 granule formulation (WD Pharma) to the reference drug Pradaxa® capsule (BI, Germany) under fed conditions in healthy subjects.


Description:

The study will comprise of a medical Screening visit, two 2-night (3-day) Treatment Periods, 2 outpatient visits, and a Follow-up visit. Each Treatment visit will be separated by a washout of up to 7 days. The Follow-up visit will occur approximately 7 days (±1) following the last study drug administration. The duration of subject participation, including screening, will be approximately 8 weeks.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date December 6, 2021
Est. primary completion date June 6, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Healthy males and females according to the following criteria: based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead; electrocardiogram (ECG), clinical laboratory tests. 2. Ages of 18 and 55 years, inclusive, who have a minimum body weight of 50.0 kg (110.0 lbs.) and = 100 kg (220 lbs.). 3. Body Mass Index (BMI) between 18.0 and 29.0 kg/m2, inclusive. 4. Negative urine pregnancy test in women of childbearing potential who are not actively breastfeeding, do not plan to become pregnant during the study, and agree to use an approved method of birth control (abstinence from heterosexual activity that could result in conception, hormonal contraceptives, condom with spermicide, diaphragm or cervical cap with spermicide, or intrauterine device) for the duration of study participation; or women of nonchildbearing potential who are > 1 year postmenopausal with follicle-stimulating hormone in the postmenopausal range. 5. Willingness of male subjects to use barrier contraception (condom with spermicide) and refrain from donating sperm, for the duration of study participation. 6. Normal coagulation function (prothrombin time [PT] and partial thromboplastin time [PTT] < 1.2 x upper limit of normal of normal [ULN] laboratory reference range). 7. Normal hepatic function (alanine aminotransferase [ALT] < 1.2 × ULN; total bilirubin level < 2 × ULN). 8. Normal renal function (estimated glomerular filtration rate > 60 mL/min/1.73 m2). 9. Ability to understand informed consent, which must be signed before any study-related procedures are performed in accordance with Good Clinical Practice (GCP) and the local legislation. Exclusion Criteria: 1. Clinically significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders. 2. Clinically significant surgery of gastrointestinal tract or evidence of significant gastrointestinal motility problems that could affect absorption of the drug. 3. Diseases of the central nervous system (included but not limited to any kind of seizures; stroke or psychiatric disorders). 4. Any history or evidence of blood dyscrasia, hemorrhagic diathesis, severe thrombocytopenia, cerebrovascular hemorrhage, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with hemorrhagic tendencies. 5. History of significant orthostatic hypotension, fainting spells or blackouts. 6. Chronic or relevant acute infections. 7. History of allergy/hypersensitivity (including drug allergy in particular to study drug or its excipients) which is deemed relevant to the trial as judged by the Principal Investigator (i.e., an Ontario-licensed physician) or Sub-Investigator (Ontario-licensed physician and/or Nurse Practitioner).. 8. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial. 9. Alcohol abuse (more than 20 g/day). 10. Drug abuse. 11. Blood donation (more than 100 mL within four weeks prior to administration or during the trial); 12. Participation in another trial with an investigational drug within four weeks prior to administration or during the trial. 13. Any laboratory value outside the reference range that is of clinical significance or positive drug or virus screening. 14. Planned surgeries within four weeks following the end-of study examination; and 15. Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding within days before or after end-of study examination.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
WD-1602
dabigatran etexilate mesylate granules for oral suspension
Pradaxa®
dabigatran etexilate capsules

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hong Kong WD Pharmaceutical Co., Limited

Outcome

Type Measure Description Time frame Safety issue
Primary AUC0-t area under the plasma concentration-time curve from time 0 to time t pre-dose (baseline) and day 1, day 2, day 3 post-dose at designed time intervals.
Primary AUC0-inf area under the concentration-time curve from time 0 to time infinity pre-dose (baseline) and day 1, day 2, day 3 post-dose at designed time intervals.
Primary Cmax the maximum concentration pre-dose (baseline) and day 1, day 2, day 3 post-dose at designed time intervals.
See also
  Status Clinical Trial Phase
Recruiting NCT04010955 - Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)
Recruiting NCT04673695 - A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 Phase 1
Completed NCT03893591 - A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
Completed NCT03895502 - Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study Phase 4
Completed NCT03154489 - Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care N/A
Completed NCT04305821 - Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics
Recruiting NCT06020560 - Study of Low Molecular Weight Heparins Phase 4
Not yet recruiting NCT05788900 - Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration Phase 1
Not yet recruiting NCT05788913 - Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration Phase 1
Terminated NCT03172546 - Determinants of Oral Anticoagulants' Activity
Recruiting NCT03772457 - Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
Completed NCT03323320 - Evaluation of Patient's Knowledge of Their NACO Treatment N/A
Recruiting NCT04257487 - Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) Phase 3
Completed NCT04272723 - Management of Venous Thromboembolism in France: a National Survey Among Vascular Medicine Physicians
Recruiting NCT04867200 - A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers Phase 1